METTL3 and breast cancer: miR-26b exhibits consistently low levels, while METTL3, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and high mobility group AT-hook 2 (HMGA2) demonstrate elevated levels in BC [25].